AMPD1: A Potential Drug Target and Biomarker for Neurological Disorders

Target Name: AMPD1

NCBI ID: G270

AMPD1

AMPD1: A Potential Drug Target and Biomarker for Neurological Disorders

AMPD1 (AMPD1_HUMAN), also known as ALDH1 gene, is a gene that encodes a protein known as the aryl hydrocarbon receptor 1 (ALDH1). The ALDH1 gene is a member of the Aryl hydrocarbon receptor gene family, which is responsible for the production of aromatic amines, which are known to have a variety of cellular effects.

AMPD1 is expressed in many tissues and cells throughout the body, including the liver, lung, and intestine. It is also highly expressed in the brain, where it is thought to play a role in the development and progression of certain neurological disorders, such as Alzheimer's disease and Parkinson's disease.

AMPD1 has also been shown to be involved in the regulation of various cellular processes, including cell signaling, DNA replication, and cell death. It has been shown to interact with a variety of proteins, including tyrosine kinase 3 (TK3), which is known to play a role in the regulation of cell growth and differentiation.

AMPD1 has also been shown to be a potential drug target in the treatment of various neurological disorders, including Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders. By targeting the ALDH1 gene, researchers hope to develop new treatments for these debilitating conditions.

One way that researchers are targeting AMPD1 as a drug target is through the use of small molecules, which are drugs that can interact with the ALDH1 protein. Researchers have identified a number of small molecules that have been shown to interact with AMPD1 and have the potential to be used as drug candidates for the treatment of neurological disorders.

Another approach that researchers are taking to target AMPD1 is through the use of genetic modification techniques. Scientists have used CRISPR-Cas9 to modify the DNA of cells and introduce small changes to the ALDH1 gene. This technique allows researchers to introduce changes to the gene that can alter its function and potentially make it a more effective drug target.

AMPD1 is also being targeted by researchers as a potential biomarker for the diagnosis and prognosis of certain neurological disorders. By analyzing the levels of AMPD1 in tissues and cells, researchers can gain insights into the health of the brain and help to identify potential diagnostic or therapeutic targets.

In conclusion, AMPD1 is a gene that has the potential to be a drug target and biomarker for the treatment of a variety of neurological disorders. As research continues to advance, it is likely that new treatments and therapies will be developed that target AMPD1 and its associated proteins.

Protein Name: Adenosine Monophosphate Deaminase 1

Functions: AMP deaminase plays a critical role in energy metabolism

The "AMPD1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about AMPD1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets